IDEAYA Biosciences has announced the pricing of a stock offering valued at $300 million. The biotechnology company intends to utilize the proceeds from this offering to advance its clinical development programs and support its ongoing research initiatives. The offering is expected to enhance the company's financial position and facilitate its strategic objectives in the biopharmaceutical sector.
Related Articles
Don't miss out on breaking stories and in-depth articles.